Literature DB >> 23955111

B-cell function after unrelated umbilical cord blood transplantation using a minimal-intensity conditioning regimen in patients with X-SCID.

Satoru Kumaki1, Yoji Sasahara, Yoshiro Kamachi, Hideki Muramatsu, Tomohiro Morio, Kumiko Goi, Kanji Sugita, Tomonari Urabe, Hidetoshi Takada, Seiji Kojima, Shigeru Tsuchiya, Toshirou Hara.   

Abstract

Patients with X-linked severe combined immunodeficiency (X-SCID) suffer from severe and persistent infections, and usually die early in life unless treated by hematopoietic stem cell transplantation. If a patient has an HLA-identical sibling donor, preparative conditioning is not necessary for T-cell engraftment and B-cell function. However, in the absence of such a donor, long-term reconstitution of full B-cell function is often problematic, leading in many cases to a lifetime requirement for immunoglobulin replacement therapy. Preparative myeloablative conditioning has been shown to improve long-term B-cell function, but may aggravate pre-existing infection and transplant-related toxicity. It is thus important to determine the minimum intensity of conditioning that assures immunoglobulin production. In the present study, we performed reduced-intensity conditioning (RIC), consisting of fludarabine 125 mg/m(2) and melphalan 80 mg/m(2), prior to unrelated umbilical cord blood transplantation (UCBT) for five patients with X-SCID, none of them had an HLA-identical donor. Four patients survived more than 4 years without sequelae, and none required long-term immunoglobulin replacement therapy. One patient succumbed to sepsis in conjunction with severe GVHD. Our result demonstrates that the RIC regimen described above in combination with UCBT is an effective and less toxic conditioning to correct B-cell function in patients with X-SCID.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23955111     DOI: 10.1007/s12185-013-1408-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  16 in total

1.  Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood?

Authors:  Juliana F Fernandes; Vanderson Rocha; Myriam Labopin; Benedicte Neven; Despina Moshous; Andrew R Gennery; Wilhelm Friedrich; Fulvio Porta; Cristina Diaz de Heredia; Donna Wall; Yves Bertrand; Paul Veys; Mary Slatter; Ansgar Schulz; Ka Wah Chan; Michael Grimley; Mouhab Ayas; Tayfun Gungor; Wolfram Ebell; Carmem Bonfim; Krzysztof Kalwak; Pierre Taupin; Stéphane Blanche; H Bobby Gaspar; Paul Landais; Alain Fischer; Eliane Gluckman; Marina Cavazzana-Calvo
Journal:  Blood       Date:  2012-02-03       Impact factor: 22.113

Review 2.  The long quest for neonatal screening for severe combined immunodeficiency.

Authors:  Rebecca H Buckley
Journal:  J Allergy Clin Immunol       Date:  2012-01-24       Impact factor: 10.793

3.  Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan.

Authors:  Tomohiro Morio; Yoshiko Atsuta; Daisuke Tomizawa; Tokiko Nagamura-Inoue; Koji Kato; Tadashi Ariga; Keisei Kawa; Kazutoshi Koike; Hisamichi Tauchi; Michiko Kajiwara; Toshiro Hara; Shunichi Kato
Journal:  Br J Haematol       Date:  2011-05-14       Impact factor: 6.998

Review 4.  Severe combined immunodeficiency. A model disease for molecular immunology and therapy.

Authors:  Alain Fischer; Françoise Le Deist; Salima Hacein-Bey-Abina; Isabelle André-Schmutz; Geneviève de Saint Basile; Jean-Pierre de Villartay; Marina Cavazzana-Calvo
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

Review 5.  B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review.

Authors:  Rebecca H Buckley
Journal:  J Allergy Clin Immunol       Date:  2010-04       Impact factor: 10.793

6.  Long-term chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: A single-center study of 22 patients.

Authors:  E Haddad; F Le Deist; P Aucouturier; M Cavazzana-Calvo; S Blanche; G De Saint Basile; A Fischer
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

7.  Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis.

Authors:  Mary Dell Railey; Yuliya Lokhnygina; Rebecca H Buckley
Journal:  J Pediatr       Date:  2009-10-09       Impact factor: 4.406

8.  Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen.

Authors:  Kanchan Rao; Persis J Amrolia; Alison Jones; Catherine M Cale; Paru Naik; Doug King; Graham E Davies; H Bobby Gaspar; Paul A Veys
Journal:  Blood       Date:  2004-09-14       Impact factor: 22.113

9.  Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.

Authors:  Karin C Straathof; Kanchan Rao; Matthias Eyrich; Geoff Hale; Prudence Bird; Eleanor Berrie; Lucinda Brown; Stuart Adams; Paul G Schlegel; Nicholas Goulden; H Bobby Gaspar; Andrew R Gennery; Paul Landais; E G Davies; Malcolm K Brenner; Paul A Veys; Persis Jal Amrolia
Journal:  Lancet       Date:  2009-09-02       Impact factor: 79.321

10.  Bone marrow transplantation for severe combined immune deficiency.

Authors:  Eyal Grunebaum; Evelina Mazzolari; Fulvio Porta; Daniela Dallera; Adelle Atkinson; Brenda Reid; Luigi D Notarangelo; Chaim M Roifman
Journal:  JAMA       Date:  2006-02-01       Impact factor: 56.272

View more
  4 in total

1.  Hematopoietic Cell Transplantation for Severe Combined Immunodeficiency Patients: a Japanese Retrospective Study.

Authors:  Satoshi Miyamoto; Katsutsugu Umeda; Mio Kurata; Akira Nishimura; Masakatsu Yanagimachi; Masataka Ishimura; Maho Sato; Tomonari Shigemura; Motohiro Kato; Yoji Sasahara; Akihiro Iguchi; Takashi Koike; Yoshiyuki Takahashi; Michiko Kajiwara; Masami Inoue; Yoshiko Hashii; Hiromasa Yabe; Koji Kato; Yoshiko Atsuta; Kohsuke Imai; Tomohiro Morio
Journal:  J Clin Immunol       Date:  2021-08-27       Impact factor: 8.317

2.  Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.

Authors:  Akira Nishimura; Yuki Aoki; Yasuyoshi Ishiwata; Takuya Ichimura; Junichi Ueyama; Yuta Kawahara; Takahiro Tomoda; Maiko Inoue; Kazuaki Matsumoto; Kento Inoue; Haruka Hiroki; Shintaro Ono; Motoi Yamashita; Tsubasa Okano; Mari Tanaka-Kubota; Miho Ashiarai; Satoshi Miyamoto; Reiji Miyawaki; Chika Yamagishi; Mari Tezuka; Teppei Okawa; Akihiro Hoshino; Akifumi Endo; Masato Yasuhara; Takahiro Kamiya; Noriko Mitsuiki; Toshiaki Ono; Takeshi Isoda; Masakatsu Yanagimachi; Daisuke Tomizawa; Masayuki Nagasawa; Shuki Mizutani; Michiko Kajiwara; Masatoshi Takagi; Hirokazu Kanegane; Kohsuke Imai; Tomohiro Morio
Journal:  J Clin Immunol       Date:  2021-02-01       Impact factor: 8.317

3.  A novel, long-lived, and highly engraftable immunodeficient mouse model of mucopolysaccharidosis type I.

Authors:  Daniel C Mendez; Alexander E Stover; Anthony D Rangel; David J Brick; Hubert E Nethercott; Marissa A Torres; Omar Khalid; Andrew Ms Wong; Jonathan D Cooper; James V Jester; Edwin S Monuki; Cian McGuire; Steven Q Le; Shih-Hsin Kan; Patricia I Dickson; Philip H Schwartz
Journal:  Mol Ther Methods Clin Dev       Date:  2015-02-11       Impact factor: 6.698

Review 4.  Considerations in Preparative Regimen Selection to Minimize Rejection in Pediatric Hematopoietic Transplantation in Non-Malignant Diseases.

Authors:  Robert J Hayashi
Journal:  Front Immunol       Date:  2020-10-19       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.